Phaseline

Targets › OPRM1

OPRM1 (Mu-type opioid receptor): drug programs, companies and trials

102 programs from 83 companies in 486 trials: 156 Phase 4, 140 Phase 2, 126 Phase 1, 64 Phase 3; Other, Psychiatry, Oncology; next expected readout Nov 2026.

Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. (UniProt, P35372)

Open in Phaseline: the race on OPRM1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mayo ClinicBCG Solution
Glucagon-like peptide 1 receptor agonist
GLP1R, Ion channels, CD38, OPRM1, PDCD1, CD274Phase 4Pain, Postoperative; Limb Pain, Phantom; Healthy; Respiratory Function Loss …Nov 2026
Brigham and Women's HospitalMIB 626 (NMN)
Serotonin transporter inhibitor; Serotonin 2a (5-HT2a) receptor antagonist; Serotonin 2c (5-HT2c) receptor antagonist
SLC5A2, SLC6A2, GLP1R, UNKNOWN, Tubulin, OPRM1, NR3C2, AGTR1, IL4R, SLC6A4, HTR2A, HTR2CPhase 4Prostate Cancer; Stable Coronary Disease; Allergic Contact Dermatitis; Hypertension …Nov 2026
Meri MircetaMorphine
Mu opioid receptor agonist
OPRM1Phase 4Colorectal CarcinomaNov 2026
Rush University Medical CenterSufentanil
Mu opioid receptor agonist
OPRM1Phase 4Minor Surgical Procedures With Monitored Anesthesia CareNov 2026
Pamukkale Universityremifentanil
Mu opioid receptor agonist
OPRM1Phase 4Tracheal ExtubationNov 2026
University of Pennsylvania2-[18F]-FA
Voltage-gated calcium channel modulator
CHRNA4, OPRK1, OPRD1, OPRM1, UL51, ADRA2A, ADRA2C, ADRA2B, Ion channels, CACNB4, CACNB2, CACNB1, CACNB3, TNF, SLC6A4, HTR2A, HTR2C, FKBP1A, CD86, CD80, PDE4A, PDE4D, PDE4B, PDE4C, PDE3A, CHRNB2, STNPhase 4Alcohol Use Disorder; Acute Kidney Injury; Insomnia; Giant Cell Arteritis …Nov 2026
Universidad Nacional Autonoma de HondurasTramadol Hydrochloride
Mu opioid receptor agonist
OPRM1Phase 4Labor PainNov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
Xiangya Hospital of Central South UniversityTegileridine Fumarate Injection
Biased μ-opioid receptor agonist
OPRM1Phase 4Pain, PostoperativeDec 2026
M.D. Anderson Cancer Center[18F]-4FN
PARP 1, 2 and 3 inhibitor
PARP1, PARP3, PARP2, CHRNB2, CHRNA4, Tubulin, OPRM1, CD274Phase 4Lymphoma; Tobacco Use Cessation; Cigarette Smoking-Related Carcinoma; Hematopoietic and Lymphoid Cell Neoplasm …Dec 2026
M.D. Anderson Cancer CenterMethylnaltrexone
Mu opioid receptor antagonist
OPRM1Phase 4Head and Neck Squamous Cell CarcinomaDec 2026
Indiana Universitymethadone
Mu opioid receptor agonist
OPRM1Phase 4Free Flap Reconstruction; Testicular CancerDec 2026
Inonu UniversityRemifentanil
Mu opioid receptor agonist
OPRM1Phase 4Hemodynamic ResponseFeb 2027
University of MichiganHydromorphone
Mu opioid receptor agonist
OPRM1Phase 4SurgeryFeb 2027
University of MichiganMorphine
Mu opioid receptor agonist
OPRM1Phase 4SurgeryFeb 2027
Unity Health TorontoMethadone
Mu opioid receptor agonist
OPRM1Phase 4Spinal SurgeryMar 2027
Montefiore Medical Centerbuprenorphine-naloxone
Partial mu-opioid receptor agonist with naloxone opioid antagonist
OPRM1Phase 4Opioid Use DisorderMar 2027
Tianjin Medical University General HospitalOliceridine
Mu opioid receptor agonist
OPRM1Phase 4Chronic Postsurgical PainMar 2027
Nordsjaellands HospitalRemifentanil
Mu opioid receptor agonist
OPRM1Phase 4Tracheal IntubationApr 2027
Brandon KnoppMethadone
Mu opioid receptor agonist
OPRM1Phase 4Pain, PostoperativeApr 2027
Anne Juul WikkelsøMorphine
Mu opioid receptor agonist
OPRM1Phase 4Caesarean SectionMay 2027
Northwestern UniversityMorphine Sulfate
Mu opioid receptor agonist
OPRM1Phase 4Pain, PostoperativeJun 2027
Duke UniversityMethadone hydrochloride
Mu opioid receptor agonist
OPRM1Phase 4Cleft Palate; Pain, PostoperativeJun 2027
Columbia UniversityNaltrexone-Bupropion Combination
Opioid receptor antagonist (naltrexone) combined with norepinephrine-dopamine reuptake inh
OPRM1, SLC6A3Phase 4ObesityJun 2027
The Methodist Hospital Research InstituteMorphine
Mu opioid receptor agonist
OPRM1Phase 4Anterior Cruciate Ligament TearJul 2027
Northwestern UniversityHydromorphone
Mu opioid receptor agonist
OPRM1Phase 4Ventral HerniaSep 2027
The Cleveland ClinicMethadone
Mu opioid receptor agonist
OPRM1Phase 4Post Operative PainOct 2027
Peking Union Medical College HospitalTegileridine
μ-opioid receptor-biased agonist
OPRM1Phase 4Scoliosis; AdolescenceOct 2027
Indiana Universitysufentanil
Mu opioid receptor agonist
OPRM1Phase 4Free Flap ReconstructionNov 2027
Murdoch Childrens Research InstituteMorphine
Mu opioid receptor agonist
OPRM1Phase 4Patient-Controlled AnalgesiaDec 2027
M.D. Anderson Cancer CenterHydromorphone
Mu opioid receptor agonist
OPRM1Phase 4Hematopoietic and Lymphoid Cell NeoplasmDec 2027
University Hospital, LimogesSufentanil
Mu opioid receptor agonist
OPRM1Phase 4Laparoscopic Cholecystectomy SurgeryJan 2028
AdventHealthMethadone
Mu opioid receptor agonist
OPRM1Phase 4Total Knee ArthroplastyApr 2028
Yale UniversityMethadone
Mu opioid receptor agonist
OPRM1Phase 4Opioid Use DisorderDec 2028
Currax PharmaceuticalsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4ObesityJan 2029
OHSU Knight Cancer InstituteMethadone
Mu opioid receptor agonist
OPRM1Phase 4Head and Neck CarcinomaJul 2029
The Royal's Institute of Mental Health ResearchContrave
Naltrexone/Bupropion combination; naltrexone is a mu-opioid receptor antagonist and buprop
OPRM1, SLC6A2, SLC6A3Phase 4Obesity–
Endeavor HealthHydromorphone
Mu opioid receptor agonist
OPRM1Phase 4EKG-QT Prolongation–
Nova Scotia Health AuthorityHydromorphone
Mu opioid receptor agonist
OPRM1Phase 4Pain, Postoperative–
Hospital Central do FunchalMorphine
Mu opioid receptor agonist
OPRM1Phase 4Analgesia Obstetrical–
The Metis FoundationMorphine
Mu opioid receptor agonist
OPRM1Phase 4Wound of Skin–
First Affiliated Hospital, Sun Yat-Sen UniversityMorphine
Mu opioid receptor agonist
OPRM1Phase 4Patients Undergoing Major Laparoscopic Abdominal Surgery–
Medical University of SilesiaMorphine
Mu opioid receptor agonist
OPRM1Phase 4Analgesics, Opioid–
University of California, San DiegoMorphine
Mu opioid receptor agonist
OPRM1Phase 4Hepatic Resection–
Universiti Sains MalaysiaMorphine
Mu opioid receptor agonist
OPRM1Phase 4Effect of Drug–
Khon Kaen UniversityMorphine Sulfate
Mu opioid receptor agonist
OPRM1Phase 4Pruritus Caused by Drug–
Middle Tennessee Research InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Low Back Pain–
University of Colorado, DenverNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Harm Reduction–
Friends Research Institute, Inc.Naloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
Pouya AzarNaloxone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 4Opioid Use Disorder–
Shiyou WeiOliceridine (TRV130)
Mu opioid receptor agonist
OPRM1Phase 4Cough–
Centre Hospitalier Universitaire, AmiensSufentanil
Mu opioid receptor agonist
OPRM1Phase 4Chronic Postsurgical Pain–
Second Affiliated Hospital, Zhejiang University, School of MedicineTegileridine Fumarate
μ-opioid receptor agonist
OPRM1Phase 4Postoperative Pain–
Endeavor Healthmethadone
Mu opioid receptor agonist
OPRM1Phase 4EKG-QT Prolongation; Quality of Recovery Scores–
Ensysce BiosciencesOxycodone (PF614)
Mu opioid receptor agonist
OPRM1Phase 3Postoperative Pain, Acute; Pharmacokinetics; Laparoscopic Hysterectomy; Liquid Oxycodone …Nov 2026
University of Maryland, BaltimoreNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Opioid Use Disorder; PainNov 2026
Medical University of South CarolinaMethadone Hydrochloride
Mu opioid receptor agonist
OPRM1Phase 3Post Operative PainDec 2026
Indiana UniversityMorphine
Mu opioid receptor agonist
OPRM1Phase 3Testicular CancerDec 2026
Adneuris TherapeuticsCebranopadol
Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist
OPRL1, OPRK1, OPRD1, OPRM1Phase 3Pain; Chronic PainJan 2027
University Hospital, Clermont-FerrandSufentanil
Mu opioid receptor agonist
OPRM1Phase 3Pain ManagementApr 2027
Memorial Sloan Kettering Cancer CenterMethadone
Mu opioid receptor agonist
OPRM1Phase 3Spinal SurgeryJun 2027
University of TorontoMorphine
Mu opioid receptor agonist
OPRM1Phase 3Arthroplasties, Knee ReplacementJul 2027
Trevi TherapeuticsNalbuphine
Opioid receptors; mu/kappa/delta agonist
OPRK1, OPRD1, OPRM1Phase 3Idiopathic Pulmonary Fibrosis; Refractory Chronic Cough; Laryngoscopy; Postoperative Pain, Acute …Aug 2027
Hans BahlmannMorphine
Mu opioid receptor agonist
OPRM1Phase 3Other Specified Disorders of Kidney and UreterOct 2027
The First Hospital of Jilin UniversityTegileridine (tegileridine fumarate injection, IV)
Biased μ-opioid receptor agonist
OPRM1Phase 3Pain ManagementOct 2027
Jason SperryFentanyl Citrate
Mu opioid receptor agonist
OPRM1Phase 3Traumatic InjuryJul 2028
University Hospital, GrenobleSufentanil
Mu opioid receptor agonist
OPRM1Phase 3Brain-dead Organ DonorsSep 2028
Memorial Sloan Kettering Cancer Centeralvimopan
Mu opioid receptor antagonist
OPRM1Phase 3Bladder CancerNov 2028
Senthil SadhasivamMethadone
Mu opioid receptor agonist
OPRM1Phase 3Idiopathic ScoliosisJan 2029
Senthil SadhasivamMethadone-based ERAS
Opioid analgesic (mu receptor agonist) administered intraoperatively and postoperatively f
OPRM1Phase 3Pediatric Cardiac SurgeryJan 2029
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) ProgramMethadone
Mu opioid receptor agonist
OPRM1Phase 3Neonatal Opioid Withdrawal Syndrome–
Brugmann University HospitalMethadone Hydrochloride
Mu opioid receptor agonist
OPRM1Phase 3Orthopedic Surgery–
Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) ProgramMorphine
Mu opioid receptor agonist
OPRM1Phase 3Neonatal Opioid Withdrawal Syndrome–
AgelessRxNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 3Healthspan Improvement; Longevity; Human Immunodeficiency Virus; Obesity; Drug …–
Murdoch Childrens Research InstituteRemifentanil
Mu opioid receptor agonist
OPRM1Phase 3Anesthesia–
AlkermesSamidorphan
Mu opioid receptor antagonist; Kappa opioid receptor partial agonist; Delta opioid receptor partial agonist
OPRM1, OPRK1, OPRD1Phase 3Schizophrenia–
Avenue TherapeuticsTramadol (AVE-901)
Mu opioid receptor agonist
OPRM1Phase 3Pain Management; Shoulder Arthropathy; Postoperative Pain; Post-surgical Pain …–
Wayne State UniversityMorphine
Mu opioid receptor agonist
OPRM1Phase 2Opioid AbuseDec 2026
University of IowaHydromorphone
Mu opioid receptor agonist
OPRM1Phase 2LaparotomyDec 2026
Medical University of LublinNaltrexone Hydrochloride
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2VulvodyniaDec 2026
New York State Psychiatric InstituteNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderJan 2027
University of Maryland, BaltimoreMethadone
Mu opioid receptor agonist
OPRM1Phase 2Opioid Use DisorderJun 2027
University of British ColumbiaNaloxone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 2Opioid-use DisorderDec 2027
KK Women's and Children's HospitalMeperidine
Mu opioid receptor agonist
OPRM1Phase 2Depression, PostpartumDec 2027
KK Women's and Children's HospitalMorphine
Mu opioid receptor agonist
OPRM1Phase 2Respiratory Depression; PainDec 2027
KK Women's and Children's HospitalRemifentanil
Mu opioid receptor agonist
OPRM1Phase 2Depression, PostpartumDec 2027
University of British Columbiamethadone
Mu opioid receptor agonist
OPRM1Phase 2Chemotherapy-induced Peripheral Neuropathy–
ReacX PharmaceuticalsNalmefene
Mu opioid receptor antagonist; Delta opioid receptor antagonist; Kappa opioid receptor partial agonist
OPRM1, OPRD1, OPRK1Phase 1Opioid Abuse and Addiction; Behavioural AddictionDec 2026
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolHydromorphone
Mu opioid receptor agonist
OPRM1Phase 1Acute Chest PainDec 2026
University Hospital, GrenobleMorphine
Mu opioid receptor agonist
OPRM1Phase 1Chronic Obstructive Pulmonary DiseaseJun 2027
Boulder CareBuprenorphine
Mu opioid receptor agonist; Kappa opioid receptor agonist
OPRM1, OPRK1Phase 1Opioid Use Disorder; Postoperative Pain; Pain, Postoperative; Acute Postoperative Pain …Aug 2027
University of Pennsylvania[11C]Carfentanil
Mu opioid receptor agonist radiotracer
OPRM1Phase 1HealthySep 2027
M.D. Anderson Cancer CenterLoperamide
Mu opioid receptor agonist
OPRM1Phase 1ColitisDec 2027
Ashish P Thakrar, MD MSMethadone hydrochloride
Mu opioid receptor agonist
OPRM1Phase 1Opioid Use Disorder (OUD)Dec 2027
ShionogiNaldemedine
Mu opioid receptor antagonist
OPRM1Phase 1Opioid-Induced Constipation (OIC)Jun 2028
John KirkwoodAxelopran
Peripherally restricted mu-opioid receptor antagonist (PAMORA)
OPRM1Phase 1Unresectable Cutaneous MelanomaJul 2028
Akyso TherapeuticsNaltrexone
Opioid receptors; mu/kappa/delta antagonist
OPRK1, OPRD1, OPRM1Phase 1Opioid Use DisorderOct 2029
Haiphong University of Medicine and PharmacyDW-1021
Fixed-dose combination of nonsteroidal anti-inflammatory drug and opioid analgesic
PTGS1, PTGS2, OPRM1Phase 1Healthy Volunteer–
Lee's PharmaceuticalFentanyl
Mu opioid receptor agonist
OPRM1Phase 1Cancer; Vaginal Delivery; Spinal Anesthesia Duration; Effect of Drug …–
Inventage Lab.IVL3004
Opioid receptor antagonist (long-acting injection)
OPRM1Phase 1Opioid Dependence–
Inventage Lab.IVL4002
Opioid receptor antagonist (long-acting injection)
OPRM1Phase 1Opioid Dependence–
Minia UniversityMorphine
Mu opioid receptor agonist
OPRM1Phase 1Post-operative Pain Management–

Conditions

Opioid Use Disorder (28) Pain, Postoperative (8) Obesity (6) Acute Myeloid Leukemia (6) Opioid-use Disorder (5) Alcohol Use Disorder (5) Analgesia (5) Pain (4) Bladder Cancer (4) Opioid Use Disorder (OUD) (4) Surgery (4) Prostate Cancer (4)

Modalities

small molecule (94), mixed (5)

Companies

M.D. Anderson Cancer Center (4) KK Women's and Children's Hospital (3) Indiana University (3) Memorial Sloan Kettering Cancer Center (2) Northwestern University (2) Endeavor Health (2) University of British Columbia (2) Murdoch Childrens Research Institute (2) University of Michigan (2) University Hospital, Grenoble (2) University of Maryland, Baltimore (2) Inventage Lab. (2) Senthil Sadhasivam (2) University of Pennsylvania (2) Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program (2) Columbia University (1) Hospital Central do Funchal (1) The Metis Foundation (1) Middle Tennessee Research Institute (1) Meri Mirceta (1)

Related targets

OPRK1 (17) OPRD1 (16) HTR2A (3) CHRNB2 (3) CHRNA4 (3) SLC6A3 (2) AGTR1 (2) PDCD1 (2) SLC6A2 (2) GLP1R (2) Tubulin (2) SLC6A4 (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.